Research on bacteriophages goes back a century, however, the discovery and widespread application of antibiotics prevented its further development. The recent and alarming rise of antibiotic-resistant infections coupled with the inability of conventional therapy to deal with the situation has led to a renewed interest in phages.
In response to this and in anticipation of a growing demand for phage products and therapies, we are determined to establish a state-of-the art R&D and manufacturing facilities built to GMP and GLP guidelines in order to provide a platform for the further development of the re-emerging field of bacteriophages.